BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23776681)

  • 21. EVI1 carboxy-terminal phosphorylation is ATM-mediated and sustains transcriptional modulation and self-renewal via enhanced CtBP1 association.
    Paredes R; Schneider M; Stevens A; White DJ; Williamson AJK; Muter J; Pearson S; Kelly JR; Connors K; Wiseman DH; Chadwick JA; Löffler H; Teng HY; Lovell S; Unwin R; van de Vrugt HJ; Smith H; Kustikova O; Schambach A; Somervaille TCP; Pierce A; Whetton AD; Meyer S
    Nucleic Acids Res; 2018 Sep; 46(15):7662-7674. PubMed ID: 29939287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
    Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
    Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
    Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
    Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.
    Lugthart S; Figueroa ME; Bindels E; Skrabanek L; Valk PJ; Li Y; Meyer S; Erpelinck-Verschueren C; Greally J; Löwenberg B; Melnick A; Delwel R
    Blood; 2011 Jan; 117(1):234-41. PubMed ID: 20855866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression.
    Ohyashiki JH; Ohyashiki K; Shimamoto T; Kawakubo K; Fujimura T; Nakazawa S; Toyama K
    Blood; 1995 Jun; 85(12):3713-8. PubMed ID: 7780155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
    Fears S; Mathieu C; Zeleznik-Le N; Huang S; Rowley JD; Nucifora G
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1642-7. PubMed ID: 8643684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
    Yoshimi A; Goyama S; Watanabe-Okochi N; Yoshiki Y; Nannya Y; Nitta E; Arai S; Sato T; Shimabe M; Nakagawa M; Imai Y; Kitamura T; Kurokawa M
    Blood; 2011 Mar; 117(13):3617-28. PubMed ID: 21289308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EVI1 protein interaction dynamics: Targetable for therapeutic intervention?
    Paredes R; Doleschall N; Connors K; Geary B; Meyer S
    Exp Hematol; 2022 Mar; 107():1-8. PubMed ID: 34958895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a.
    Spensberger D; Delwel R
    FEBS Lett; 2008 Aug; 582(18):2761-7. PubMed ID: 18619962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
    Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
    Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amplification and translocation of 3q26 with overexpression of EVI1 in Fanconi anemia-derived childhood acute myeloid leukemia with biallelic FANCD1/BRCA2 disruption.
    Meyer S; Fergusson WD; Whetton AD; Moreira-Leite F; Pepper SD; Miller C; Saunders EK; White DJ; Will AM; Eden T; Ikeda H; Ullmann R; Tuerkmen S; Gerlach A; Klopocki E; Tönnies H
    Genes Chromosomes Cancer; 2007 Apr; 46(4):359-72. PubMed ID: 17243162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting a DNA binding motif of the EVI1 protein by a pyrrole-imidazole polyamide.
    Zhang Y; Sicot G; Cui X; Vogel M; Wuertzer CA; Lezon-Geyda K; Wheeler J; Harki DA; Muzikar KA; Stolper DA; Dervan PB; Perkins AS
    Biochemistry; 2011 Dec; 50(48):10431-41. PubMed ID: 22039883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.
    Masamoto Y; Chiba A; Mizuno H; Hino T; Hayashida H; Sato T; Bando M; Shirahige K; Kurokawa M
    Blood Adv; 2023 Apr; 7(8):1577-1593. PubMed ID: 36269819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations in MECOM, Encoding Oncoprotein EVI1, Cause Radioulnar Synostosis with Amegakaryocytic Thrombocytopenia.
    Niihori T; Ouchi-Uchiyama M; Sasahara Y; Kaneko T; Hashii Y; Irie M; Sato A; Saito-Nanjo Y; Funayama R; Nagashima T; Inoue S; Nakayama K; Ozono K; Kure S; Matsubara Y; Imaizumi M; Aoki Y
    Am J Hum Genet; 2015 Dec; 97(6):848-54. PubMed ID: 26581901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EVI1, a target gene for amplification at 3q26, antagonizes transforming growth factor-β-mediated growth inhibition in hepatocellular carcinoma.
    Yasui K; Konishi C; Gen Y; Endo M; Dohi O; Tomie A; Kitaichi T; Yamada N; Iwai N; Nishikawa T; Yamaguchi K; Moriguchi M; Sumida Y; Mitsuyoshi H; Tanaka S; Arii S; Itoh Y
    Cancer Sci; 2015 Jul; 106(7):929-37. PubMed ID: 25959919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myeloid transforming protein Evi1 interacts with methyl-CpG binding domain protein 3 and inhibits in vitro histone deacetylation by Mbd3/Mi-2/NuRD.
    Spensberger D; Vermeulen M; Le Guezennec X; Beekman R; van Hoven A; Bindels E; Stunnenberg H; Delwel R
    Biochemistry; 2008 Jun; 47(24):6418-26. PubMed ID: 18500823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of EVI1 in myeloid malignancies.
    Glass C; Wilson M; Gonzalez R; Zhang Y; Perkins AS
    Blood Cells Mol Dis; 2014; 53(1-2):67-76. PubMed ID: 24495476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis.
    Senyuk V; Zhang Y; Liu Y; Ming M; Premanand K; Zhou L; Chen P; Chen J; Rowley JD; Nucifora G; Qian Z
    Proc Natl Acad Sci U S A; 2013 Apr; 110(14):5594-9. PubMed ID: 23509296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
    Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
    Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of binding sites of EVI1 in mammalian cells.
    Yatsula B; Lin S; Read AJ; Poholek A; Yates K; Yue D; Hui P; Perkins AS
    J Biol Chem; 2005 Sep; 280(35):30712-22. PubMed ID: 16006653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.